A rapid, accurate and robust UHPLC-MS/MS method for quantitative determination of BMS-927711, a CGRP receptor antagonist, in plasma in support of non-clinical toxicokinetic studies

- A robust assay was validated to quantify BMS-927711, a drug candidate, in plasma.
- A simplified method optimization strategy was used to develop this robust assay.
- An N-carbamoyl glucuronide metabolite was evaluated to minimize its conversion risk.
- Excellent assay robustness, precision and accuracy were achieved.
- It has been applied to non-clinical toxicokinetic studies in different species.